On November 20, 2024 Schrodinger, Inc. (Nasdaq: SDGR) reported that management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference (Press release, Schrodinger, NOV 20, 2024, View Source [SID1234648533]). The live presentation will take place on Wednesday, December 4, 2024 at 8:30 a.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live webcast can be accessed in the "Investors" section of Schrödinger’s website and will be archived for approximately 90 days following the event.

On November 20, 2024 Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, reported the initiation of its ALISertib in CAncer (ALISCA-Breast1) Phase II trial (PUMA-ALI-1201; NCT06369285) of alisertib in combination with endocrine therapy for the treatment of patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-negative) recurrent or metastatic breast cancer who have been previously treated with CDK 4/6 inhibitors and received at least two prior lines of endocrine therapy in the recurrent or metastatic setting (Press release, Puma Biotechnology, NOV 20, 2024, View Source [SID1234648532]). The ALISCA-Breast1 trial will enroll up to 150 patients who will be randomized (1:1:1) to receive alisertib dosed at either 30 mg, 40 mg or 50 mg twice daily on days 1-3, 8-10 and 15-17 in a 28-day cycle in combination with the endocrine therapy of the investigator’s choice. Patients must provide blood and tissue specimens so that biomarkers can be analyzed.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Additional therapies are needed for patients with HER2-negative, HR+ metastatic breast cancer whose disease progresses on CDK4/6 inhibitors in the first-line setting"

The primary objective of the trial is to determine the optimal alisertib dose in combination with selected endocrine therapy. The primary endpoints of the trial include objective response rate, duration of response, disease control rate, progression-free survival, and overall survival. As a secondary endpoint, Puma will evaluate each of these efficacy endpoints within biomarker subgroups in order to determine whether any biomarker subgroup correlates with response. Puma will perform its biomarker analysis of the ALISCA-Breast1 trial in parallel with the execution of the clinical trial. Puma plans to perform an initial interim analysis for the evaluation of safety and efficacy.

Based upon the outcomes of the trial, Puma anticipates meeting with the U.S. Food and Drug Administration to explore the potential for an approval pathway for alisertib in HER2-negative, HR+ metastatic breast cancer. Once the optimal alisertib dose is identified, Puma plans to engage with global regulatory agencies regarding the design of a pivotal (Phase III) trial, which it anticipates will be a randomized trial of alisertib plus investigator’s choice endocrine therapy versus placebo plus investigator’s choice endocrine therapy in patients with HER2-negative, HR+ metastatic breast cancer.

"Additional therapies are needed for patients with HER2-negative, HR+ metastatic breast cancer whose disease progresses on CDK4/6 inhibitors in the first-line setting," said Joyce A. O’Shaughnessy, M.D., the Celebrating Women Chair in Breast Cancer Research at Baylor University Medical Center, Texas Oncology, Sarah Cannon Research Institute in Dallas, Texas. "The results from the TBCRC 041 trial indicated that alisertib has impressive clinical activity in the setting of endocrine therapy and CDK4/6 inhibitor-resistant metastatic breast cancer, with good tolerability. I look forward to the further evaluation of alisertib in the ALISCA-Breast1 trial to definitively determine the clinical impact of this treatment."

Alan H. Auerbach, Chief Executive Officer, President and Founder of Puma, stated, "We are excited to initiate this Phase II trial and to move forward with the development of alisertib in HER2-negative HR+ metastatic breast cancer. We believe that the data from the previous trial of alisertib monotherapy (published in Lancet Oncology) as well as the TBCRC 041 trial (published in JAMA Oncology), which tested alisertib alone and with fulvestrant, and the randomized trial of alisertib plus paclitaxel versus paclitaxel alone (published in JAMA Network Open) have demonstrated that alisertib is active in patients with HER2-negative, HR+ metastatic breast cancer and in biomarker focused subgroups. We look forward to enrollment in the ALISCA-Breast1 trial and anticipate that we should have initial data from this trial in 2025."

On November 20, 2024 Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, reported an upcoming oral presentation at the 66th ASH (Free ASH Whitepaper) Annual Meeting taking place from December 7-10, 2024, in San Diego, CA (Press release, Remix Therapeutics, NOV 20, 2024, View Source [SID1234648531]). Results demonstrate oral dosing of REM-422, a selective mRNA degrader of the MYB oncogene, leads to robust anti-leukemic activity observed both as a monotherapy and in combination across a genetically diverse set of preclinical models of acute myeloid leukemia (AML), including eradication of AML blasts in engrafted patient-derived xenograft (PDX) models of AML. The presentation also highlights the differentiated mechanism of action of REM-422 as it can be combined effectively with other agents used in the treatment of AML/MDS and retains activity in cell models engineered with mutations known to confer resistance to other targeted agents.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The preclinical data for REM-422 provide strong therapeutic rationale for our ongoing Phase I study in AML and High-Risk MDS," said Peter Smith, Ph.D., President and Chief Executive Officer of Remix Therapeutics. "REM-422 is the first compound from our REMaster platform to enter clinical development. Its unique mechanism of action, coupled with the robust anti-leukemic activity observed both as a monotherapy and in combination, positions REM-422 as a promising candidate to address the unmet needs in these patient populations."

The MYB oncogenic transcription factor plays a crucial role in hematopoietic cell differentiation and proliferation. Its dysregulation and aberrant activity have been identified in various cancers, including adenoid cystic carcinoma (ACC), AML, acute lymphoblastic leukemia (ALL), and lymphoma. In AML, functional genomics studies have demonstrated a lineage-wide dependency on MYB, consistent with its involvement in disease driven by multiple oncogenic abnormalities (e.g. MLLr, NPM1, FLT3, p53, etc.).

REM-422 is a first-in-class, potent, selective, oral small molecule degrader of MYB mRNA currently in clinical development for AML/HR-MDS (NCT06297941) and ACC (NCT06118086). It functions by inducing the inclusion of a normally unused ‘poison exon’ (PE) in the MYB pre-mRNA transcript, activating the nonsense-mediated decay pathway and preventing MYB protein expression.

Details for the oral presentation are as follows:

Title: REM-422, a Small Molecule MYB mRNA Degrader, Demonstrates Anti-Leukemic Activity As Monotherapy and in Combination with Standards of Care in Preclinical Models of AML
Speaker: Samantha Levin-Furtney, Scientist, Remix Therapeutics
Session: 604- Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: New Targets and Drugs
Date: Monday, December 9, 2024
Time: 3:30 PM (Session time: 2:45-4:15 PM)
Location: Manchester Grand Hyatt San Diego, Seaport Ballroom ABCD

About REM-422
REM-422 is a first-in-class, potent, selective, and oral small molecule mRNA degrader that induces the reduction of MYB mRNA and subsequent protein expression. REM-422 functions by facilitating the incorporation of poison exons within the mRNA transcript, leading to nonsense-mediated decay (NMD) of the transcript. REM-422 addresses MYB dysregulation, a driver of oncogenesis, upstream of protein expression.

About AML/HR-MDS
Acute myeloid leukemia (AML), a rare cancer of the blood and bone marrow, is the most common type of acute leukemia in adults. AML is caused by genetic mutations within bone marrow cells, which in turn causes the production of leukemic white blood cells that crowd out healthy blood cells. This may cause problems with bleeding, infection, and anemia. Myelodysplastic Syndromes (MDS) are disorders of blood-forming units in the bone marrow. High-risk (HR)-MDS patients have a higher percentage of blast cells in the bone marrow and that, in many cases, progresses to AML. There are several approved agents to treat AML, however, many patients relapse after achieving a response, underscoring the need for new therapies.

On November 20, 2024 the National Medical Products Administration (NMPA) reported on its official website that the NMPA approved the listing of Zorifertinib Hydrochloride Tablets (trade name: Zorifer), a Class 1 innovative drug, developed by Alpha Biopharma (Press release, Alpha Biopharma, NOV 20, 2024, View Source [SID1234648530]). This product is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) accompanied with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 (L858R) substitution mutation and central nervous system (CNS) metastases.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Zorifertinib is the first drug in the world to launch a registration clinical trial specifically for advanced NSCLC with CNS metastases and achieve remarkable results. It is also the only* EGFR tyrosine kinase inhibitor (EGFR-TKI) currently available that was explicitly designed as non-blood-brain barrier efflux protein substrates and can penetrate the blood-brain barrier 100%.

The EVEREST trial, an international multi-center randomized controlled phase III trial of Zorifertinib, demonstrated its superior ability to control intracranial lesions. The trial enrolled patients with more severe disease, most of whom had EGFR L858R mutations or had more than 3 intracranial lesions. Zorifertinib showed a significant benefit in overall progression-free survival (PFS), with intracranial PFS reaching 17.9 months, and it significantly reduced the risk of intracranial progression/death by 37% (P = 0.0018). Furthermore, Zorifertinib demonstrated consistent and significant benefits in subgroups of patients with intracranial symptoms, EGFR L858R mutations, and more than 3 intracranial lesions.

As the global lead Principal Investigator (PI) for the EVEREST study, Professor Wu Yilong from Guangdong Provincial People’s Hospital mentioned that while several drugs have been approved for EGFR mutated NSCLC, there is still a lack of clinical head-to-head randomized controlled studies specifically targeting drug therapy for lung cancer with CNS metastases. The EVEREST study is the world’s first large-scale registered international multi-center clinical trial for the treatment of lung cancer with CNS metastases, and it has achieved statistically significant positive results. In the study, the therapeutic advantages of Zorifertinib in various subgroups were observed, and it was verified that all people with EGFR mutated NSCLC and brain metastases could benefit from Zorifertinib therapy. Among patients who were treated with third-generation TKI after progression, a trend of benefit in overall survival was also observed, suggesting that the combination or sequential therapy with third-generation TKI is expected to bring a better prognosis.

Zhang Yong, CEO of Alpha Biopharma, stated that the company is dedicated to developing innovative drugs that are urgently needed in clinical practice. We have collaborated with AstraZeneca to develop Zorifertinib, aiming to address the unmet clinical needs of patients with lung cancer and CNS metastases. Zorifertinib has demonstrated its therapeutic value during the clinical stage and has received support from clinical experts and regulatory authorities. It has become the world’s first approved new generation EGFR-TKI specifically targeting lung cancer with CNS metastases. The company anticipates that Zorifertinib will significantly enhance patient care in the future, offering more effective treatments for individuals with lung cancer and brain metastases.

About Lung Cancer and Central Nervous System Metastasis

In China, lung cancer is the most common and deadliest malignant tumor. In 2022, there were about 1.06 million new cases of lung cancer diagnosed, leading to approximately 730,000 deaths, with non-small cell lung cancer (NSCLC) accounting for around 85% of all cases. In the Chinese NSCLC population, about 38.4% of patients have been found to have EGFR mutation-positive, which is identified as one of the driving genes for NSCLC formation.

Central nervous system metastasis is a common occurrence in NSCLC patients, with approximately 25% of EGFR mutation-positive NSCLC patients having CNS metastases at the time of initial diagnosis. Additionally, 20% to 65% of lung cancer patients will develop CNS metastases during the course of their disease. Poor blood-brain barrier permeability of therapeutic drugs is one of the reasons why patients experience CNS progression during treatment.

About Blood-Brain Barrier and Efflux Proteins

The blood-brain barrier is a protective shield that prevents drugs from entering the brain. It is made up of tightly packed brain capillary endothelial cells, surrounded by pericellular, astrocyte terminal, and basement membrane structures. This barrier has high resistance and low permeability, making it challenging for drugs to reach the brain. As a result, the brain can act as a safe haven for tumor cells, contributing to the progression of central nervous system (CNS) diseases.

The blood-brain barrier contains a large number of efflux proteins, such as P-glycoprotein (P-gp, ABCB1) and breast cancer resistance protein (BCRP), which are crucial for drug resistance in the development of brain lesions and the survival of tumor stem cells.

Remarks:

The "only … currently available" in this article is valid as of the deadline of Oct. 10, 2024.

References

Cheng H, Perez-Soler R. Leptomeningeal metastases in non-small-cell lung cancer. Lancet Oncol. 2018 Jan;19(1):e43-e55.
Zhou Q, Yu Y, Xing L, et al. First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trial. Med. Published online October 3, 2024.
Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022[J]. Journal of the National Cancer Center, 2024.
Duma N, Santana-Davila R, Molina JR. Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. Mayo Clin Proc. 2019, 94(8):1623-1640.
Zhang YL, Yuan JQ, Wang KF, et al. Threapleton D, Yang ZY, Mao C, Tang JL. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016 Nov 29;7(48):78985-78993.
Preusser M, Winkler F, Valiente M, Manegold C, Moyal E, Widhalm G, Tonn JC, Zielinski C. Recent advances in the biology and treatment of brain metastases of non-small cell lung cancer: summary of a multidisciplinary roundtable discussion. ESMO (Free ESMO Whitepaper) Open. 2018 Jan 26;3(1):e000262.
Oncology Physician Branch of Chinese Medical Doctor Association, Oncology Branch of China International Exchange and Promotive Association for Medical and Health Care. Chinese Treatment Guidelines for Brain Metastases from Lung Cancer (2021 Edition). Chinese Journal of Oncology, 2021, 43(03): 269-281.
Shetty V, Babu S. Management of CNS metastases in patients with EGFR mutation-positive NSCLC. Indian J Cancer. 2019 Nov;56(Supplement):S31-S37.

On November 20, 2024 The Leukemia & Lymphoma Society (LLS) reported the company will present new data from its Beat AML Master Clinical Trial and Pediatric Acute Leukemia (PedAL) Master Clinical Trial at the 66th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition (Press release, The Leukemia & Lymphoma Society, NOV 20, 2024, View Source;lymphoma-society-lls-data-at-ash-provides-glimpse-into-the-future-of-blood-cancer-treatment-302310609.html [SID1234648529]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The findings from LLS’s convened master clinical trials show great progress and are helping shape the treatment landscape for acute leukemias. Updated results show that more than half of a group of children with relapsed acute leukemias achieved remission after receiving a combination of treatments. Additional data indicate that IDH inhibitors as single agent or in combination with low-intensity therapies may be a viable treatment option for older adults with acute leukemias.

LLS will also support its more than 150 funded researchers, as well as more than a dozen current and former LLS Therapy Acceleration Program (TAP) biotech company partners, who will present the latest updates from their ongoing clinical trials.

"For 75 years, LLS has funded physician-scientists and researchers who take risks, think big and test bold ideas," says Lee Greenberger, Ph.D., LLS’s Chief Scientific Officer. "Our strategic investments have helped advance more than 70% of blood cancer treatments approved by the FDA over the past 20 years and I am encouraged to see how the latest data at ASH (Free ASH Whitepaper) will lead to remarkable advances for patients."

Health equity is also a major focus of findings from several investigators funded through the LLS Equity in Access and IMPACT grant programs, which:

Show that there’s significant underrepresentation of women and racial and ethnic minorities in clinical trial enrollment
Provide patient recommendations on how to address disparities in people living with multiple myeloma
Share insights on how to address barriers to opening clinical trials in a community-oncology setting
Demonstrate the disparities in access to care and services depending on the type of insurance coverage.
"LLS has an incredible track record of success across its research, health equity, patient advocacy, and education and support services," says E. Anders Kolb, M.D., The Leukemia & Lymphoma Society’s President and CEO. "The breadth of research we support every year at ASH (Free ASH Whitepaper) reinforces our commitment to improve and extend the lives of blood cancer patients and accelerate progress."

Gwen Nichols, M.D., LLS’s Chief Medical Officer, will join a panel at the Annual ASH (Free ASH Whitepaper) Clinicians in Practice luncheon on December 8, 2024, focused on the future of artificial intelligence in blood cancer.

Drs. Kolb, Nichols and Greenberger are available to provide perspectives on pivotal data presented at ASH (Free ASH Whitepaper), including the promise of menin inhibitors to change the leukemia treatment landscape.

Following is an overview of compelling data from LLS that will be presented at ASH (Free ASH Whitepaper):

Reshaping How Adults with Acute Myeloid Leukemia are Treated

Nearly 1,600 patients with AML have received genomic screening within seven days of diagnosis and more than 500 have enrolled in one of the many Beat AML precision treatment subtrials, which so far have targeted 15 distinct types of AML.

Patients enrolled in Beat AML have achieved improved survival and better quality of life compared to patients receiving standard-of-care chemotherapy.

Beat AML also recently opened its first clinical subtrial to investigate the safety and efficacy of lomonitinib (ZE46-0134) in patients with FLT3-mutated relapsed or refractory AML in partnership with Eilean Therapeutics.

These new findings from Beat AML subtrials will be presented at ASH (Free ASH Whitepaper):

Title & Poster Number

Date/Time

Location

Poster 1564 – Demographics, Characteristics, Survival and Outcomes in Older, Untreated, Acute Myeloid Leukemia Patients with NPM1 Mutations or KMT2A rearrangements from the Beat AML Master Clinical Trial

Saturday, Dec. 7, 2024

5:30-7:30 PM

San Diego Convention Center

Halls G-H

Poster 4324 – Outcomes and Survival in Newly Diagnosed, Older, Acute Myeloid Leukemia Patients from the Beat AML Master Trial in the Venetoclax/Azacitidine Age

Monday, Dec. 9, 2024

6:00-8:00 PM

San Diego Convention Center

Halls G-H

Poster 4325 – IDH2 Mutation Is Associated with Favorable Outcome Among Older Adults with Newly Diagnosed Acute Myeloid Leukemia Treated with Lower-Intensity Therapy

Monday, Dec. 9, 2024

6:00-8:00 PM

San Diego Convention Center

Halls G-H

LLS Executive Research Strategy Lead Ashley Yocum, Ph.D., is available to discuss Beat AML findings.

Revolutionizing the Treatment and Care of Children with Blood Cancer

LLS’s PedAL is fundamentally revolutionizing how children with pediatric leukemia are being treated while building a foundation that addresses major roadblocks to care.

LLS will present updated findings from the PedAL Screening Trial (APAL2020SC), which is actively enrolling in the U.S., Canada, Australia, and New Zealand. This LLS-convened and led screening trial assesses individual clinical and biological characteristics that can inform a family’s choice of standard treatment or enrolling in a clinical trial.

In addition to the PedAL Screening Trial, a treatment trial is open across 74 international sites. LLS anticipates the opening of a second PedAL global treatment trial soon.

Title & Poster Number

Date/Time

Location

Poster 4233 – Molecular Features, Treatments and Outcomes for Pediatric AML Patients from APAL2020SC Pediatric Acute Leukemia (PedAL) Screening Trial

Monday, Dec. 9, 2024

6:00-8:00 PM

San Diego Convention Center

Halls G-H

Chief Medical Officer Gwen Nichols, M.D., is available to provide updates on LLS PedAL and provide perspective on important clinical data coming out of ASH (Free ASH Whitepaper).

Driving the Latest Blood Cancer Developments Through Research Funding

Blood cancer physician-scientists and researchers are transforming the way we treat this disease, but they cannot do this groundbreaking work alone. LLS is helping to lead this charge by funding some of the most innovative research projects around the world focused on bringing blood cancer patients much needed new treatments.

LLS currently provides more than $300 million in academic biomedical research grants to investigators across 16 countries and 30 U.S. states to accelerate how we treat all blood cancers. LLS recently announced its latest round of multi-year grants, which includes research into the development of leukemia in children with Down syndrome.

Here are some of the latest research advances across a variety of blood cancers that several LLS grantees will present at ASH (Free ASH Whitepaper):

Title & Poster Number

Date/Time

Location

Oral 969 – Venetoclax Plus Azacitidine for Newly Diagnosed Younger Acute Myeloid Leukemia Patients Independent of Fitness for Intensive Chemotherapy

Monday, Dec. 9, 2024

5:00 PM

Manchester Grand Hyatt San Diego, Grand Hall B

Oral 321 – Machine Learning Derived Three-Parameter Prognostic Model for Survival in Patients with BPDCN

Saturday, Dec. 7, 2024

4:30 PM

Manchester Grand Hyatt San Diego, Seaport Ballroom EFGH

Oral 1011 – Combined Pirtobrutinib, Venetoclax, and Obinutuzumab As First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Monday, Dec. 9, 2024

5:00 PM

Marriott Marquis San Diego Marina, Grand Ballroom 8-9

Oral 739 – Follicular Dendritic Cells Represent a Therapeutic Vulnerability in Early Follicular Lymphoma

Monday, Dec. 9, 2024

10:30 AM

Marriott Marquis San Diego Marina, Grand Ballroom 5-6

Oral 102 – Acute GvHD of the Gut Is Associated with Minor Histocompatibility Antigens Cross-Reactive Against Gut-Tropic Viral Epitopes

Saturday, Dec. 7, 2024

10:45 AM

San Diego Convention Center Ballroom 20CD

Oral 671 – A High-Fiber Dietary Intervention (NUTRIVENTION) in Precursor Plasma Cell Disorders Improves Biomarkers of Disease and May Delay Progression to Myeloma

Sunday, Dec. 8, 2024

5:30 PM

Marriott Marquis San Diego Marina, Pacific Ballroom Salons 24-26

Oral 755 – JAK2V617F Mutant MPN Cells Support Parallel Evolution of Independent Leukemic Clones

Monday, Dec. 9, 2024

11:30 AM

Manchester Grand Hyatt San Diego, Grand Hall C

Oral 857 – A Multiomic Analysis of Waldenstrom’s Macroglobulinemia Identifies Three Subtypes of Disease Based on Impaired Plasma Cell Differentiation

Monday, Dec. 9, 2024

3:45 PM

Marriott Marquis San Diego Marina, Pacific Ballroom Salons 18-19

Poster 3127 – Favorable Safety Profile and Durable Responses to Pmb-CT01 (BAFFR-CAR T Cell) Therapy in Patients with B-Cell Lymphomas Ineligible for or Who Failed CD19-Targeted Therapy, Including CD19-Negative Disease

Sunday, Dec. 8, 2024

6:00-8:00 PM

San Diego Convention Center

Halls G-H

Addressing Healthcare Disparities Means a Better Future for Everyone with Blood Cancer

LLS believes every blood cancer patient and survivor should be able to access the care they need when they need it. LLS is addressing healthcare disparities to ensure everyone has a better future through three signature programs:

The Equity in Access Research Program, which provides funding for health services research that seeks to uncover and ultimately address the social, economic, and environmental disadvantages that stand in the way of patients with and survivors of a blood cancer accessing high-quality cancer care and services.
Influential Medicine Providing Access to Clinical Trials (IMPACT) provides funding to major cancer centers around the U.S. to collaborate with community-based hospitals and clinics to bring quality blood cancer clinical trials significantly closer to underrepresented patients.
Underrepresented Minority Medical Student (URM) Research programs, launched in 2023, aim to provide medical students from groups underrepresented in biomedical science the opportunity to participate in blood cancer research and benefit from mentorship that the program also provides. The URM program’s first grantee, Jennifer Lewis, is a co-author on an abstract that has developed a new CAR-T product that shows early promise in treating acute myeloid leukemia.
LLS proudly and gratefully acknowledges the leadership support of Royalty Pharma and the following companies for their support of the Equity in Access Research Program and other initiatives focused on reducing healthcare disparities in blood cancer care and treatment: AstraZeneca Pharmaceuticals LP, Lilly and Bristol Myers Squibb.

Title & Poster Number

Date/Time

Location

IMPACT Grants

Oral 784 – Bringing Hematological Malignancy Clinical Trials to Patients: Mayo Clinic LLS Impact

Monday, Dec. 9, 2024

11:15 AM

Marriott Marquis San Diego Marina, San Diego Ballroom AB

Poster 2322 – Chive-Impact: Establishing the Clonal Hematopoiesis and Inflammation in the Vasculature (CHIVE) Registry and Biorepository in Underserved Areas

Saturday, Dec. 7, 2024

5:30-7:30 PM

San Diego Convention Center

Halls G-H

Equity in Access

Oral 786 – Real-World Analysis of Insurer Rejection Rates for Specialty Oral Anticancer Prescriptions in a Nationwide Sample of Patients with Blood Cancer

Monday, Dec. 9, 2024

11:45 AM

Marriott Marquis San Diego Marina, San Diego Ballroom AB

Oral 792 – Impact of Fee-for-Service Versus Managed Care Medicare Insurance on the Quality of End-of-Life Care Among Older Adults with Blood Cancers

Monday, Dec. 9, 2024

11:45 AM

Manchester Grand Hyatt San Diego, Seaport Ballroom EFGH

Health Services

Poster 5100 – Disparities in phase 2 and 3 clinical trial enrollment for hematologic malignancies

Monday, Dec. 9, 2024

6:00-8:00 PM

San Diego Convention Center

Halls G-H

Poster 5113 – Disparities in clinical trial participation among Medicare beneficiaries with hematologic malignancies from 2006 to 2019: a SEER-Medicare analysis

Monday, Dec. 9, 2024

6:00-8:00 PM

San Diego Convention Center

Halls G-H

Partner Projects

Poster 2383 – A Patient Perspective on Actionable Steps to Address Disparities in Healthcare Among US Patients with Multiple Myeloma

Saturday, Dec. 7, 2024

5:30-7:30 PM

San Diego Convention Center

Halls G-H

URM

Oral 371 – Development of CAR T Cells Targeting U5snRNP200 for the Treatment of Acute Myeloid and B-Lymphoid Leukemias

Saturday, Dec. 7, 2024

5:00 PM

Manchester Grand Hyatt San Diego, Grand Hall C

Senior Vice President of Education Services & Health Research Elisa Weiss, Ph.D., is available to provide perspective on health equity research presented at ASH (Free ASH Whitepaper).

Taking Risks to Accelerate the Development of Innovative Blood Cancer Therapies

LLS TAP provides funding to biotech companies to accelerate the development of innovative blood cancer treatments with the promise of changing the standard of care for blood cancer. As a strategic venture philanthropy program, LLS TAP can invest in research that venture capitalists find too risky.

Since 2017, five LLS TAP-supported therapies have been approved by the FDA or included in the National Comprehensive Cancer Network guidelines. Here are some of the latest research advances across a variety of blood cancers that several LLS TAP company partners will showcase at ASH (Free ASH Whitepaper):

Title & Poster Number

Date/Time

Location

Oral 214 – Ziftomenib Combined with Intensive Induction (7+3) in Newly Diagnosed NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007

Saturday, Dec. 7

2:45 PM

San Diego Convention Center, Ballroom 20CD

Oral 980 – Results from the First Phase 1 Clinical Study of DR-01, a Non-Fucosylated Anti-CD94 Targeting Antibody in Patients with Relapsed/Refractory Cytotoxic Lymphomas: Dose Escalation and Optimization

Monday, Dec. 9, 2024

4:45 PM

Marriott Marquis San Diego Marina, Pacific Ballroom Salons 15-17

Oral 1008 – IO-202, a Novel Anti-LILRB4 Antibody, with Azacitidine for Hypomethylating Agent-Naive Chronic Myelomonocytic Leukemia: Phase 1b Expansion Cohort Results

Monday, Dec. 9, 2024

5:45 PM

Manchester Grand Hyatt San Diego, Grand Hall D

Poster 2876 – ICT01, an Investigational γ9δ2 T Cell Activator, Added to Azacitidine-Venetoclax Achieves Frequent and Early Complete Remissions in Adults with AML Unfit for Intensive Induction Chemotherapy: Interim Results from the Ongoing Open-Label, Randomized Phase 1 Study Eviction

Sunday, Dec. 8, 2024

6:00-8:00 PM

San Diego Convention Center

Halls G-H

Poster 3052 – Investigating the Novel Combination of the Innate Cell Engager (ICE) Acimtamig with Off-the-Shelf Allogeneic Natural Killer Cells AlloNK in Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Initial Results of the Phase 2 Luminice-203 Study

Sunday, Dec. 8, 2024

6:00-8:00 PM

San Diego Convention Center

Halls G-H

Poster 4265 – Encouraging Efficacy of Bexmarilimab with Azacitidine in Relapsed or Refractory MDS in Bexmab Ph1/2 Study

Monday, Dec. 9, 2024

6:00-8:00 PM

San Diego Convention Center

Halls G-H

Poster 4395 – EO2463 Peptide Immunotherapy in Patients with Newly Diagnosed Asymptomatic Follicular Lymphoma Results in Monotherapy Objective Clinical Responses Linked with Anti-Peptide Specific CD8 Memory T Cell Responses: The EONHL1-20/Sidney Study

Monday, Dec. 9, 2024

6:00-8:00 PM

San Diego Convention Center

Halls G-H

Poster 4433 – Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Leukemia, and Solid Tumors

Monday, Dec. 9, 2024

6:00-8:00 PM

San Diego Convention Center

Halls G-H